Ertugliflozin/sitagliptin - Merck/Pfizer

Drug Profile

Ertugliflozin/sitagliptin - Merck/Pfizer

Alternative Names: MK 8835/MK 0431; MK 8835A; STEGLUJAN

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co; Pfizer
  • Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Type 2 diabetes mellitus

Most Recent Events

  • 01 Mar 2018 Registered for Type-2 diabetes mellitus in European Union (PO)
  • 25 Jan 2018 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of ertugliflozin/sitagliptin for Type-2 diabetes mellitus in European Union
  • 22 Dec 2017 Expected launch in USA in January 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top